淋巴结检出数对口腔鳞癌死亡风险的预测价值
该回顾性队列研究纳入1080例接受颈淋巴结清扫的口腔鳞癌患者,评估淋巴结检出数(LNY)对3年和5年死亡率的预测准确性。ROC曲线分析和交叉验证均显示LNY未改善预后预测准确性,平均治疗效应模型也未发现不同LNY组间3年死亡风险存在显著差异,提示LNY作为预后或手术质量指标的适用性存疑。
要点
- LNY未改善口腔鳞癌3年和5年死亡风险的预测准确性。
- 跨中心交叉验证显示加入LNY未提升回归模型预测效能。
- pN阳性患者中不同LNY组3年死亡风险无显著差异。
核心结论
- 在不同设置下考虑LNY均未改善对死亡率的预后预测准确性。
- 显著的跨中心变异和缺乏一致的生存获益挑战LNY作为预后或手术质量指标的使用。
研究设计与样本
- 回顾性队列研究,纳入1080例接受颈淋巴结清扫的原发口腔鳞癌患者,来自Brescia、Cork和Heidelberg三个中心。
主要发现
- ROC曲线分析显示LNY未改善预测3年和5年死亡风险的预后准确性。
- 跨独立队列交叉验证显示,将LNY加入二项回归模型未改善预测准确性。
- 以LNY范围33至44为参照,平均治疗效应模型发现pN阳性患者中LNY各组(2-17、17-25、25-33、44-119)3年死亡风险无显著差异。
关键数值与推荐
- ROC曲线下面积(AUC)用于评估LNY预测3年和5年死亡率的准确性。
- 采用二项回归模型并校正LNY及多种混杂因素进行跨队列交叉验证。
临床怎么用
- 基于现有证据,不宜将LNY单独作为口腔鳞癌预后判断或手术质量的可靠指标。
局限性
- 研究为回顾性设计。
- 存在显著的跨中心变异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Lymph nodal yield (LNY) is increasingly used in oral squamous cell carcinoma (OSCC) research as a prognostic factor and quality metric but remain to be validated across independent OSCC cohorts. STUDY DESIGN: Retrospective cohort study. SETTING: Primary OSCC patients (n = 1080) who underwent a neck dissection, collected from three sites: Brescia, Cork, and Heidelberg. METHODS: The accuracy of LNY in predicting 3- and 5-year mortality was evaluated using the area under the ROC curve (AUC). Binomial regression models, adjusted for LNY and various confounders, were used to cross-validate predictive performance across independent cohorts. A model estimating the population-average treatment effect of LNY was used to estimate the effect of what would have been observed if the OSCC patients had been randomly assigned to have specific ranges of LNYs removed, irrespective of their individual characteristics. Mean LNY was estimated between the three cohorts. RESULTS: ROC curve analysis demonstrated that LNY did not improve prognostic accuracy in predicting 3- and 5-year mortality risks. Cross-validation across independent cohorts showed that adding LNY to the binomial regression models did not improve predictive accuracy. Using the LNY range of 33 to 44 as a reference, the average treatment effect model found no significant difference in the 3-year risk of death across LNY groups (LNY: 2-17, 17-25, 25-33, and 44-119) for pN-positive patients. CONCLUSION: We found no improvement in the prognostic accuracy for mortality when considering LNY in different settings. Substantial inter-center variability and lack of consistent survival benefit challenge the use of LNY as a prognostic or surgical quality metric.
引用
- Mirian C, Jensen LR, Hald M, et al. Lymph Nodal Yield and Prediction of Mortality in Oral Squamous Cell Carcinoma Patients. Otolaryngol Head Neck Surg. 2025. PMID: 41104839. doi:10.1002/ohn.70040
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。